The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

New research suggests a genetic mutation previously believed to promote esophageal cancer might actually play a protective ...

Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Many cancers, including PDAC, are driven by mutations in the RAS family of oncogenes – genes that, when altered, promote cancer. Researchers have long sought drugs that target the actions of mutant ...

No matter where it starts in your body, cancer is caused by changes (or mutations) in certain genes that cause some of your cells to grow and multiply out of control. Usually, your body has ways ...

The evidence that recurrent SNVs or CDNs are common in true cancer driver genes is convincing, with more limited evidence that many more undiscovered cancer driver mutations will have CDNs, and that ...